{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:36:15Z","timestamp":1759941375062,"version":"3.38.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p> Denosumab (formerly AMG 162) is a fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-\u03baB ligand, a cytokine member of the tumor necrosis factor family that is the primary mediator of osteoclastic bone resorption. Increased bone resorption is a prominent feature in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders. Denosumab inhibits the action of receptor activator of nuclear factor-\u03baB ligand, thereby reducing the differentiation, activation and survival of osteoclasts, and slowing the rate of bone resorption. Postmenopausal women with low bone mineral density treated with denosumab have an increase in bone mineral density and a reduction of bone turnover markers that is rapid, sustained and reversible. In patients with multiple myeloma and bone metastases from breast cancer, denosumab reduces bone turnover to a similar magnitude but in a more sustained manner than intravenous pamidronate. Denosumab is well tolerated with adverse events similar to placebo. Denosumab is a promising investigational agent for the management of osteoporosis and other diseases associated with bone loss. <\/jats:p>","DOI":"10.2217\/17455057.2.4.517","type":"journal-article","created":{"date-parts":[[2006,6,28]],"date-time":"2006-06-28T15:02:29Z","timestamp":1151506949000},"page":"517-525","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis"],"prefix":"10.1177","volume":"2","author":[{"given":"E Michael","family":"Lewiecki","sequence":"first","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA, Tel.: +1 505 855 5525; Fax: +1 505 884 4006;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,7,1]]},"reference":[{"key":"bibr0101-17455057.2.4.517","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"bibr1-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650100202"},{"key":"bibr2-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650070902"},{"key":"bibr3-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1627-0"},{"key":"bibr4-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1514-0"},{"key":"bibr5-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.18.2165"},{"key":"bibr6-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200312000-00005"},{"key":"bibr7-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.005"},{"key":"bibr8-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1502-4"},{"key":"bibr9-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1652-z"},{"volume-title":"Bone Health and Osteoporosis: a report of the Surgeon General.","year":"2004","author":"US Department of Health and Human Services","key":"bibr10-17455057.2.4.517"},{"key":"bibr11-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040305"},{"key":"bibr12-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1933"},{"key":"bibr13-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044459"},{"key":"bibr010001-17455057.2.4.517","unstructured":"First study to show that denosumab reduced bone turnover and increased bone mineral density (BMD) in postmenopausal women with low BMD. Further investigation continues with Phase III trials to evaluate the safety and efficacy of denosumab for the prevention and treatment of postmenopausal osteoporosis and other skeletal disorders"},{"key":"bibr14-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041114"},{"key":"bibr15-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00502-1"},{"key":"bibr16-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1762"},{"key":"bibr17-17455057.2.4.517","first-page":"2060","volume":"87","author":"Meunier PJ","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"bibr18-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.020"},{"key":"bibr19-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"key":"bibr20-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000149165.99974.12"},{"key":"bibr21-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"bibr22-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.4.490"},{"key":"bibr23-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1002\/art.21361"},{"key":"bibr24-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00334.x"},{"key":"bibr25-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068003"},{"key":"bibr26-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.18.2412"},{"key":"bibr27-17455057.2.4.517","unstructured":"Stolina M, Dwyer D, Morony S, Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum. S708 (2005)."},{"key":"bibr28-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.2.348"},{"key":"bibr010002-17455057.2.4.517","unstructured":"First study to demonstrate that receptor activator of nuclear factor-\u03baB ligand (RANKL) inhibition with osteoprotegerin\u2013Fc reduces bone turnover in humans with no significant adverse effects. It was elected to continue further investigation of RANKL inhibition with denosumab, a more potent antiresorptive agent with a longer duration of action"},{"key":"bibr29-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3119"},{"key":"bibr30-17455057.2.4.517","first-page":"7883","volume":"63","author":"Zhang J","year":"2003","journal-title":"Cancer Res."},{"key":"bibr31-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1038\/nature04524"},{"key":"bibr32-17455057.2.4.517","first-page":"S293","volume":"20","author":"Peterson MC","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"bibr33-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11138"},{"key":"bibr34-17455057.2.4.517","first-page":"634","volume":"112","author":"Mankarious S","year":"1988","journal-title":"J. Lab. Clin. Med."},{"key":"bibr35-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.8586"},{"key":"bibr36-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.9.7131"},{"key":"bibr37-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.9.1260"},{"key":"bibr38-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1038\/16852"},{"key":"bibr39-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.4.1566"},{"key":"bibr40-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011229324412"},{"key":"bibr41-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.10.8437"},{"key":"bibr42-17455057.2.4.517","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1359\/JBMR.050408","volume":"20","author":"Cohen SB","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"bibr43-17455057.2.4.517","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.06.005"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.2.4.517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.2.4.517","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.2.4.517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T14:44:14Z","timestamp":1741617854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.2.4.517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.2217\/17455057.2.4.517"],"URL":"https:\/\/doi.org\/10.2217\/17455057.2.4.517","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"type":"print","value":"1745-5057"},{"type":"electronic","value":"1745-5065"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}